Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases from a Canadian Perspective

Kwan, Benjamin Y. M.; Kielar, Ania Z.; El-Maraghi, Robert H.; Garcia, Lourdes M.

doi:10.1016/j.carj.2012.02.002

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in inclusion criteria and exclusion criteria may contribute to the variations in OS (e.g., patients with fewer and smaller metastases might have received a complete resection or ablation and would have a better prognosis). Long-term outcomes of RFA alone for hepatic metastases from colorectal cancer are encouraging[22]–[24], and the combination of RFA and liposomal chemotherapy is believed to increase hepatic tumor destruction and improve survival[25],[26]. For patients with a third metastatic site, such as distant lymph node metastases, prognosis was worse.…”

Section: Discussionmentioning

confidence: 99%

Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer

Sheng¹,

He²,

Li³

et al. 2014

Chin J Cancer

View full text Add to dashboard Cite

The survival of most patients with both unresectable hepatic and pulmonary metastases of colorectal cancer is poor. In this retrospective study, we investigated the efficacy of computed tomography (CT)-guided radiofrequency ablation (RFA) and systemic chemotherapy plus hepatic artery infusion of floxuridine (HAI-FUDR). Sixty-one patients were selected from 1,136 patients with pulmonary and hepatic metastases from colorectal cancer. Patients were treated with RFA and systemic chemotherapy plus HAI-FUDR (ablation group, n = 39) or systemic chemotherapy plus HAI-FUDR (FUDR group, n = 22). Patients in the two groups were matched by sex, age, number of metastases, and calendar year of RFA or FUDR. Survival data were evaluated by using univariate and multivariate analyses. Clinical characteristics were comparable between the two groups. All patients in the ablation group underwent RFA and chemotherapy. Median follow-up was 56.8 months. The 1-, 3-, and 5-year overall survival (OS) rates were 97%, 64%, and 37%, respectively, for the ablation group, and 82%, 32%, and 19%, respectively, for the FUDR group. The 1-, 3-, and 5-year survival rates after metastasis were 97%, 49%, and 26% for the ablation group, and 72%, 24%, and 24% for the FUDR group, respectively. The median OS times were 45 and 25 months for the ablation and FUDR groups, respectively. In the multivariate analysis, treatment allocation was a favorable independent prognostic factor for OS (P = 0.001) and survival after metastasis (P = 0.009). These data suggest that the addition of RFA to systemic chemotherapy plus HAI-FUDR improves the survival of patients with both unresectable hepatic and pulmonary metastases from colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer

Sheng¹,

He²,

Li³

et al. 2014

Chin J Cancer

View full text Add to dashboard Cite

show abstract

“…Most clinical data on CRLM ablation are based on experience with RFA, especially with the percutaneous approach [ 46 , 47 , 48 , 49 , 50 ]. The mRECIST criteria are the current standard methods to determine the treatment efficacy, evaluating the extent of necrosis by comparing the tumor dimensions before and after the ablative treatment [ 51 , 52 ].…”

Section: Methodsmentioning

confidence: 99%

Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach

Finotti

D’Amico

Romano

et al. 2022

JPM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common tumor worldwide and it is characterized in 20–30% of cases by liver involvement, which strongly affects the long-term patient outcome. There are many available therapies for liver colorectal metastases (CRLMs); the current standard of care is represented by liver resection, and when feasible, associated with systemic chemotherapy. Microwave thermal ablation (MWA) is a viable option in unresectable patients or to achieve treatment with a parenchymal spearing approach. A literature review was performed for studies published between January 2000 and July 2022 through a database search using PUBMED/Medline and the Cochrane Collaboration Library with the following MeSH search terms and keywords: microwave, ablation, liver metastases, colorectal neoplasm, and colon liver rectal metastases. The recurrence rate and overall patients’ survival were evaluated, showing that laparoscopic MWA is safe and effective to treat CRLMs when resection is not feasible, or a major hepatectomy in fragile patients is necessary. Considering the low morbidity of this procedure, it is a viable option to treat patients with recurrent diseases in the era of effective chemotherapy and multimodal treatments.

show abstract

“…Kwanet. al evaluated a total of 63 CRLM patients (109 tumors) treated with RFA, and they identified that average tumor-free survival was 14.4 ± 1.4 months (range, 1-43 months), and local recurrence was occurred in 31.2% of treated tumors (34/109) [16]. Microwave ablation is another technique for ablation that is used for particularly small metastases in CRLM.…”

Section: Radiofrequency and Microwave Ablationmentioning

confidence: 99%

Local Therapy Modalities in Management of Colorectal Cancer Liver Metastasis

2019

ARC Journal of Surgery

View full text Add to dashboard Cite

Liver is the most common site of metastasis in colorectal cancers, and metastatic liver disease is found nearly 25% of the patients at diagnosis. Additionally, liver metastasis occurs in approximately half of the cases during the course of the disease. Liver metastases are important in colorectal cancer morbidity and mortality. So, management of liver metastases of colorectal cancer is important. Recently, many treatment modalities have been introduced in addition to surgery. Liver-directed therapies increase treatment options and improve outcomes in metastatic disease. In this paper, we reviewed and summarized these treatment options in patients with colorectal liver metastases.

show abstract

Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases from a Canadian Perspective

Abstract: This study demonstrated good-quality outcomes for RFA treatment of colorectal cancer liver metastases from a Canadian perspective and compared favorably with published studies.

Cited by 5 publications

References 21 publications

Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer

Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer

Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach

Local Therapy Modalities in Management of Colorectal Cancer Liver Metastasis

Contact Info

Product

Resources

About